Evidence map›Paper›PMID 27245439›Full record

ArticleJournal of neuroinflammation2016

Reduced levels of alpha-1-antitrypsin in cerebrospinal fluid of amyotrophic lateral sclerosis patients: a novel approach for a potential treatment.

Uri Wormser, Jessica Mandrioli, Marco Vinceti, Nicola Fini, Amnon Sintov, Berta Brodsky, Elena Proskura, Yoram Finkelstein

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroinflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Serpin neuropathology in the P497S UBQLN2 mouse model of ALS/FTD.Brain pathology (Zurich, Switzerland) · 2021
    Article
  4. Under-recognized primary spontaneous pneumothorax in ALS: a multicenter retrospective study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2019
    Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Uri WormserInstitute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University, POB 12065, 91120, Jerusalem, Israel. wormser@cc.huji.ac.il.
Jessica MandrioliDepartment of Neuroscience, S. Agostino- Estense Hospital, and University of Modena and Reggio Emilia, Modena, Italy.
Marco VincetiResearch Centre for Environmental, Genetic and Nutritional Epidemiology (CREAGEN), University of Modena and Reggio Emilia, Modena, Italy.
Nicola FiniDepartment of Neuroscience, S. Agostino- Estense Hospital, and University of Modena and Reggio Emilia, Modena, Italy.
Amnon SintovDepartment of Biomedical Engineering, Faculty of Engineering Sciences, Ben Gurion University of the Negev, Beer Sheva, 84105, Israel.
Berta BrodskyInstitute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University, POB 12065, 91120, Jerusalem, Israel.
Elena ProskuraInstitute of Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University, POB 12065, 91120, Jerusalem, Israel.
Yoram FinkelsteinService and Unit of Neurology and Toxicology, Shaare Zedek Medical Center, Jerusalem, Israel.
Hebrew University of Jerusalem · ILUniversity of Modena and Reggio Emilia · ITBen-Gurion University of the Negev · ILShaare Zedek Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAmyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative motor neuron disease that involves activation of the immune system and inflammatory response in the nervous system. Reduced level of the immuno-modulatory and anti-inflammatory protein alpha-1-antitrypsin (AAT) is associated with inflammation-related pathologies. The objective of the present is to determine AAT levels and IL-23 in the cerebrospinal fluid (CSF) of ALS patients and control group.

findingsCSF samples from newly diagnosed ALS patients and age-matched controls were analyzed for AAT and IL-23 by ELISA and magnetic luminex screening, respectively. A statistically significant reduction of 45 % in mean AAT levels was observed in the CSF of ALS patients (21.4 μg/ml) as compared to the control group (mean 38.8 μg/ml, p = 0.013). A statistically significant increase of 30.8 % in CSF mean levels of the pro-inflammatory cytokine IL-23 was observed in ALS patients (1647 pg/ml) in comparison to the controls (1259 pg/ml, p = 0.012). A negative correlation coefficient (r = -0.543) was obtained by linear regression analysis of the two measured parameters (p = 0.036).

conclusionsReduced AAT and elevated IL-23 CSF levels support the notion of neuroinflammatory process occurring in ALS patients. Increasing AAT levels in the patients' nervous system should be further investigated as a new therapeutic approach and a novel potential tool for ALS treatment.

Indexed as

AdultAgedalpha 1-AntitrypsinAmyotrophic Lateral SclerosisBiomarkersFemaleHumansInterleukin-23MaleMiddle Agedalpha 1-AntitrypsinBiomarkersInterleukin-23ALSAmyotrophic lateral sclerosisAntitrypsinCerebrospinal fluidMNDMotor neuron disease

Identifiers

PMID27245439
PMCPMC4888657
OpenAlexW2413754170

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.